Compare Heron Therapeutics Inc (HRTX) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs ProShares UltraPro QQQ ETF — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while ProShares UltraPro QQQ ETF trades at $81.33 (market cap $38.74B). The key difference: ProShares UltraPro QQQ ETF is far larger — about 569.6× Heron Therapeutics Inc's market cap, and ProShares UltraPro QQQ ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and ProShares UltraPro QQQ ETF for 24 Days on average.
| HRTX | TQQQ | |
|---|---|---|
Market Cap | $68.01M | $38.74B |
Volume | 1,891,941 | 65,384,797 |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.49 | $87.22 |
52-Week Low | $0.27 | $37.89 |
Typical Hold Time | 35 Days | 24 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.4061, up 4.13% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics (-22.52% net margin), analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX faces significant fundamental challenges with consistent losses and negative ROE, though revenue stability provides some foundation. The strong analyst support suggests potential upside if operational improvements materialize, but high execution risk and cash flow concerns warrant caution for investors seeking near-term profitability.
TQQQ trades at $81.28, down 2.78% on the day, with technical indicators showing a bullish bias despite recent selling pressure. The ETF maintains a strong position near its pivot point of $81, supported by positive moving average signals. Recent news highlights ongoing institutional interest alongside concerns about hidden costs and volatility risks inherent in leveraged ETF structures.
The outlook remains cautiously optimistic given the bullish technical setup, though investors face significant volatility risks amplified by the 3x leverage structure. Key opportunities include exposure to Nasdaq-100 growth, while risks center on expense ratios, financing costs, and potential market corrections that could magnify losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
